Please login to the form below

Not currently logged in
Email:
Password:

Roche wins early US approval for skin cancer drug Erivedge

Erivedge is the first drug specifically registered to treat basal cell carcinoma

Roche and Genentech have been granted an earlier-than-expected approval in the US for Erivedge (vismodegib), the first drug specifically registered to treat basal cell carcinoma, the most common form of skin cancer.

The green light has come well ahead of the Food and Drug Administration's (FDA) March 8 deadline for reviewing the marketing application for Erivedge, which will be used in patients with locally advanced or metastatic disease who are not candidates for surgery or radiotherapy.

The new drug was fast-tracked by the FDA based on the results of the ERIVANCE BCC study, which showed that Erivedge shrank tumours or healed visible lesions in 43 per cent of patients with locally-advanced basal cell carcinoma and 30 per cent of patients with metastatic disease. The median progression-free survival for both metastatic and locally advanced patients was 9.5 months.

The approval is also a major milestone for Curis, the small biotech company which has devoted years to teasing out the metabolic pathway targeted by vismodegib.

The drug is a first-in-class oral treatment that selectively inhibits signalling in the Hedgehog pathway, which is implicated in more than 90 per cent of all basal cell cancers but found rarely in healthy tissues.

"Our understanding of molecular pathways involved in cancer, such as the Hedgehog pathway, has enabled the development of targeted drugs for specific diseases," commented Richard Pazdur, the director of the FDA's Office of Hematology and Oncology Products.

"This approach is becoming more common and will potentially allow cancer drugs to be developed more quickly," he added.

Curis will receive a $10m milestone payment following approval, having already booked $8m from Roche when the FDA accepted vismodegib's marketing application for review. The biotech firm will also receive 5-8 per cent royalties, depending on sales levels.

In the past, Roche has predicted that vismodegib could achieve sales of more than 1bn Swiss francs at peak.

31st January 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HealthCircle Agency Group

Hello. We’re HealthCircle - a collective group of specialist healthcare agencies with offices in London, New York and Singapore who...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....